$232 Million is the total value of DAFNA Capital Management LLC's 79 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| STXS | STEREOTAXIS INC | $26,677,000 | +80.4% | 13,680,554 | 0.0% | 11.51% | +56.5% | |
| ATRC | ATRICURE INC | $8,539,000 | -12.4% | 318,729 | 0.0% | 3.68% | -24.0% | |
| AKBA | AKEBIA THERAPEUTICS INC | $5,860,000 | +48.1% | 715,538 | 0.0% | 2.53% | +28.5% | |
| NBIX | NEUROCRINE BIOSCIENCES INC | $4,846,000 | +23.4% | 55,008 | 0.0% | 2.09% | +7.1% | |
| BLUE | BLUEBIRD BIO INC | $4,248,000 | +58.6% | 27,000 | 0.0% | 1.83% | +37.6% | |
| ARNA | ARENA PHARMACEUTICALS INC | $4,211,000 | +15.1% | 93,942 | 0.0% | 1.82% | -0.2% | |
| BHVN | BIOHAVEN PHARMACEUTICALS HOLD | $4,118,000 | +39.2% | 80,000 | 0.0% | 1.78% | +20.8% | |
| RADIUS HEALTH INCnote 3.000% 9/0 | $3,336,000 | +8.9% | 4,000,000 | 0.0% | 1.44% | -5.6% | ||
| LMNX | LUMINEX CORP | $3,184,000 | -0.4% | 138,391 | 0.0% | 1.37% | -13.6% | |
| FOMX | FOAMIX PHARMACEUTICALS LTD | $3,030,000 | +4.4% | 808,000 | 0.0% | 1.31% | -9.4% | |
| CARA | CARA THERAPEUTICS INC | $2,818,000 | +50.9% | 143,611 | 0.0% | 1.22% | +31.0% | |
| NVRO | NEVRO CORP | $1,951,000 | +60.7% | 31,210 | 0.0% | 0.84% | +39.4% | |
| SCYX | SCYNEXIS INC | $1,922,000 | +213.5% | 1,272,927 | 0.0% | 0.83% | +171.8% | |
| INSULET CORPnote 1.375% | $1,811,000 | +13.9% | 1,500,000 | 0.0% | 0.78% | -1.3% | ||
| VKTX | VIKING THERAPEUTICS INC | $1,781,000 | +29.9% | 179,200 | 0.0% | 0.77% | +12.6% | |
| VBIV | VBI VACCINES INC | $1,590,000 | +16.9% | 850,000 | 0.0% | 0.69% | +1.5% | |
| AGTC | APPLIED GENETIC TECHNOL CORP | $1,505,000 | +68.3% | 359,190 | 0.0% | 0.65% | +45.8% | |
| JNJ | JOHNSON AND JOHNSON | $1,314,000 | +8.3% | 9,400 | 0.0% | 0.57% | -6.0% | |
| ASMB | ASSEMBLY BIOSCIENCES INC | $996,000 | -12.9% | 50,573 | 0.0% | 0.43% | -24.4% | |
| SPRO | SPERO THERAPEUTICS INC | $897,000 | +108.1% | 70,000 | 0.0% | 0.39% | +80.8% | |
| ABUS | ARBUTUS BIOPHARMA CORP | $884,000 | -6.6% | 246,900 | 0.0% | 0.38% | -18.9% | |
| MDGL | MADRIGAL PHARMACEUTICALS INC | $827,000 | +11.2% | 6,600 | 0.0% | 0.36% | -3.5% | |
| CDTX | CIDARA THERAPEUTICS INC | $564,000 | +12.8% | 212,766 | 0.0% | 0.24% | -2.4% | |
| URGN | UROGEN PHARMA LTD | $554,000 | -14.2% | 15,000 | 0.0% | 0.24% | -25.5% | |
| ALDX | ALDEYRA THERAPEUTICS INC | $452,000 | +8.9% | 50,000 | 0.0% | 0.20% | -5.3% | |
| MASI | MASIMO CORPORATION | $415,000 | +28.9% | 3,000 | 0.0% | 0.18% | +11.9% | |
| STRO | SUTRO BIOPHARMA INC | $359,000 | +26.4% | 31,494 | 0.0% | 0.16% | +9.9% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $354,000 | +12.0% | 137,600 | 0.0% | 0.15% | -2.5% | |
| DEXCOM INCnote 0.750% 5/1 | $336,000 | 0.0% | 250,000 | 0.0% | 0.14% | -13.2% | ||
| ALDER BIOPHARMACEUTICALS INCnote 2.500% 2/0 | $240,000 | +19.4% | 250,000 | 0.0% | 0.10% | +4.0% | ||
| SLGL | SOL GEL TECHNOLOGIES LTD | $237,000 | +12.3% | 35,000 | 0.0% | 0.10% | -2.9% | |
| BLCM | BELLICUM PHARMACEUTICALS INC | $101,000 | +14.8% | 30,000 | 0.0% | 0.04% | 0.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.